Exit Interview: Abernethy Tells MTI Why She's Leaving FDA – But Staying On Her Own Path

The FDA’s outgoing second-in-command, Amy Abernethy, is confident she’s leaving the agency in good hands but plans to continue to advocate for patients by focusing on areas such as trial design and use of real-world evidence. In this interview with Medtech Insight, Abernethy also talks about the work she put in to make sure there was a change in IT culture at the agency, among other topics.